Is It Ozempic Gastroparesis or Something Else?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Pharmaceutical Injury Litigation

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may wonder whether these symptoms signal gastroparesis or a less serious condition. The medical community has long emphasized the importance of distinguishing drug side effects from underlying disease processes. This page clarifies the difference between common gastrointestinal symptoms and confirmed gastroparesis, helping you understand what diagnostic tests can reveal.

Understanding the Link Between Ozempic and Gastroparesis

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. However, its use has been associated with a range of gastrointestinal adverse reactions, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. Gastroparesis presents clinically with nausea, vomiting, early satiety, postprandial fullness, and abdominal pain, and can lead to severe nutritional deficiencies and impaired quality of life. The mechanistic link between Ozempic and gastroparesis is grounded in the drug's pharmacology: GLP-1 receptor agonists slow gastric emptying as part of their glucose-lowering effect, and in susceptible individuals, this effect may become pathological, resulting in symptomatic gastroparesis. Clinical trial data from the Ozempic prescribing information document a significantly higher incidence of gastrointestinal adverse reactions among treated patients compared to placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the higher dose: 34.0% for 2 mg versus 30.8% for 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include gastroparesis.

Clinical Evidence and Risk Context for Texas Patients

Additional gastrointestinal adverse reactions reported with Ozempic, each with a frequency of less than 5%, include dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0% placebo, 2.7% 0.5 mg, 1.1% 1 mg), flatulence (0.8% placebo, 0.4% 0.5 mg, 1.5% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the constellation of symptoms—particularly dyspepsia, gastroesophageal reflux disease, and nausea—overlaps significantly with gastroparesis presentation. The prescribing information also notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Ozempic and other GLP-1 receptor agonists, but these are distinct from the gastrointestinal effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical consideration. The prescribing information does not specifically mention gastroparesis as a potential adverse reaction, instead grouping it under broader gastrointestinal adverse reactions. This lack of explicit warning may leave patients and healthcare providers unaware of the risk, potentially delaying diagnosis and treatment. For affected patients in Texas, settlement-related considerations may arise if it can be demonstrated that the manufacturer failed to adequately warn about the risk of gastroparesis, leading to harm. The timeline between exposure to Ozempic and documented harm is variable; gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials, but gastroparesis may develop over weeks to months of treatment. Patients who experience persistent nausea, vomiting, or abdominal pain after starting Ozempic should be evaluated for gastroparesis, and discontinuation of the drug may be warranted. In summary, the evidence from clinical trials and prescribing information supports a mechanistic and epidemiological link between Ozempic and gastroparesis. The drug's known effect on gastric emptying, combined with the high incidence of gastrointestinal adverse reactions, underscores the need for clear warnings. Patients in Texas who have developed gastroparesis after using Ozempic may have legal recourse if they can show that inadequate warnings contributed to their injury. A thorough medical and legal evaluation is essential to assess individual cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms like nausea, vomiting, early satiety, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its mechanism, and in some individuals this effect becomes pathological, causing gastroparesis. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, with rates as high as 36.4% for the 1 mg dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What legal options do Texas patients have for Ozempic-related gastroparesis?

Texas patients who developed gastroparesis after using Ozempic may pursue a settlement if they can demonstrate that the manufacturer failed to adequately warn about the risk. The prescribing information does not explicitly mention gastroparesis, which may constitute inadequate warning. A legal evaluation is necessary to assess individual cases, including documentation of Ozempic use, gastroparesis diagnosis, and resulting harm.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.